NCT00206492 2017-08-01
Trial of ZD1839 (Iressa) and Tamoxifen in Breast Cancer Patients
Baylor Breast Care Center
Phase 2 Terminated
Clinical Trials
8 trialsNCT00086957 2017-02-27
Gefitinib, Trastuzumab, and Docetaxel in Treating Patients With Metastatic Breast Cancer
City of Hope Medical Center
Phase 1/2 Completed
NCT00082667 2013-02-25
Gefitinib Followed By Surgery in Treating Women With Ductal Carcinoma In Situ of the Breast
Vanderbilt-Ingram Cancer Center
Phase 2 Terminated
NCT00049062 2013-02-21
Anastrozole and ZD 1839 in Treating Postmenopausal Women With Metastatic Breast Cancer
The University of Texas Health Science Center at San Antonio
Phase 2 Completed
NCT00206414 2013-02-05
Arimidex/Faslodex/Iressa Study: A Trial Using Arimidex, Faslodex and Iressa in Women With Breast Cancer
Baylor Breast Care Center
Phase 2 Terminated
NCT01732276 2012-12-03
The Safety and Effects of Gefitinib in Triple-negative,EGFR Positive Metastatic Breast Cancer
Jiangmen Central Hospital
Phase 2 Unknown
NCT00080743 2009-08-06
Gefitinib With or Without Tamoxifen in Treating Patients With Tamoxifen-Resistant Metastatic Breast Cancer
Dartmouth-Hitchcock Medical Center
Phase 2 Completed
NCT00428896 2008-07-21
A Feasibility Study With Iressa in Resistant Cytokeratin-Positive Tumor Cells Circulating in the Blood of Women With Breast Cancer
University Hospital of Crete
Phase 2 Completed